RVTY

AI Research

Q4 Diagnostics +10% revenue growth; 2026 revenue guided $2.96B-$2.99B; Buy consensus

Revvity reported stronger-than-expected Q4 2025 results with Diagnostics delivering 10% reported revenue growth and issued upbeat FY2026 guidance of $2.96-$2.99B in revenue and adjusted EPS of $5.35-$5.45. The board declared a $0.07 quarterly dividend payable May 8, 2026, and UBS raised its price target to $82 from $79 on March 2. The stock is up 0.51% today at $97.57, though down 16.79% over the past month; 12 analysts maintain a Buy consensus with a $112.25 average target.